Analysts Set Expectations for Edesa Biotech Q3 Earnings

Edesa Biotech, Inc. (NASDAQ:EDSA) – Equities researchers at Zacks Research lowered their Q3 2026 earnings estimates for Edesa Biotech in a report issued on Friday, May 22nd. Zacks Research analyst D. Bautz now forecasts that the company will post earnings per share of ($0.38) for the quarter, down from their prior forecast of ($0.23). The consensus estimate for Edesa Biotech’s current full-year earnings is ($0.97) per share. Zacks Research also issued estimates for Edesa Biotech’s Q4 2026 earnings at ($0.40) EPS, FY2026 earnings at ($1.57) EPS, FY2027 earnings at ($1.13) EPS and FY2028 earnings at ($0.93) EPS.

Edesa Biotech (NASDAQ:EDSA) last posted its quarterly earnings data on Thursday, May 14th. The company reported ($0.49) EPS for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.25).

A number of other analysts have also recently weighed in on EDSA. Weiss Ratings restated a “sell (e+)” rating on shares of Edesa Biotech in a report on Friday, March 27th. Wall Street Zen cut shares of Edesa Biotech from a “hold” rating to a “sell” rating in a report on Saturday, May 16th. One equities research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Edesa Biotech currently has an average rating of “Hold” and an average price target of $5.00.

Edesa Biotech Stock Performance

Shares of NASDAQ:EDSA opened at $7.97 on Thursday. The stock has a market capitalization of $70.85 million, a price-to-earnings ratio of -5.95 and a beta of 1.26. Edesa Biotech has a 1-year low of $0.72 and a 1-year high of $20.32. The company has a 50 day moving average price of $9.19 and a 200 day moving average price of $4.49.

Hedge Funds Weigh In On Edesa Biotech

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Susquehanna International Group LLP acquired a new position in Edesa Biotech in the 3rd quarter worth approximately $36,000. State Street Corp acquired a new position in Edesa Biotech in the 4th quarter worth approximately $27,000. Diadema Partners LP acquired a new position in Edesa Biotech in the 4th quarter worth approximately $77,000. Finally, DRW Securities LLC acquired a new position in Edesa Biotech in the 4th quarter worth approximately $191,000. Institutional investors and hedge funds own 5.50% of the company’s stock.

Insider Buying and Selling

In other news, CEO Pardeep Nijhawan acquired 30,000 shares of the firm’s stock in a transaction that occurred on Friday, February 27th. The stock was purchased at an average price of $2.22 per share, with a total value of $66,600.00. Following the purchase, the chief executive officer owned 371,702 shares of the company’s stock, valued at approximately $825,178.44. This trade represents a 8.78% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available at the SEC website. Over the last three months, insiders have purchased 51,000 shares of company stock valued at $148,500. Company insiders own 24.40% of the company’s stock.

About Edesa Biotech

Edesa Biotech, Inc is a clinical-stage biotechnology company focused on the discovery and development of next-generation vaccines and immunotherapies. The company leverages a proprietary self-amplifying RNA platform to create candidates designed for both intranasal and injectable administration. Edesa’s approach aims to elicit robust mucosal and systemic immune responses, with applications spanning infectious diseases and immuno-oncology.

Among Edesa’s pipeline programs is a lead intranasal vaccine candidate targeting SARS-CoV-2, currently advancing through early-stage clinical trials.